Abstract
Background Refractory cardiogenic shock (CS) patients receiving venous-arterial extracorporeal membrane oxygenation (VA-ECMO) have a wide range of mortality, machine algorithm methods may explain the potential heterogeneity of these patients.
Methods Between January 2018 and May 2021, 210 patients with CS who were receiving VA-ECMO support were enrolled and analyzed retrospectively. The k-means consensus agnostic algorithm was used. Patients were divided into three clusters based on covariates, such as platelet count (PLT), aspartic acid transaminase (AST), Interleukin-6 (IL-6), prothrombin time (PT), and serum lactate level 24 hours after ECMO initiation. The clinical and laboratory profiles were analyzed.
Results Among 210 CS with CS receiving ECMO, 148 (70.5%) were men, with a median age of 62 years (interquartile range (IQR): 53-67). Overall, 104 (49.5%) patients survived to discharge with 142 (67.6%) survived on ECMO. The patients were phenotyped into three clusters: (1) “platelet preserved (I)” Phenotype (36 [17.1%] patients), characterized by a preserved platelet count; (2) “hyperinflammatory (II)” phenotype (72 [34.3%] patients), characterized by a significant inflammatory response with higher Interleukin-6 (IL-6), and Interleukin-10 (IL-10) levels; and (3) “hepatic-renal (III)” phenotype (102 [48.6%] patients), characterized by unfavorable conditions in creatinine, aspartic acid transaminase, alanine aminotransferase, direct bilirubin, and prothrombin time. The in-hospital mortality rates were 25.0%, 52.8%, and 55.9% for phenotypes I, II, and III, respectively (P = 0.005).
Conclusion The consensus k-means algorithm analysis identified three phenotypes in refractory patients with CS receiving VA-ECMO: “platelet preserved,” “hyperinflammatory,” and “hepatic-renal.” The phenotypes are associated with the clinical profile and mortality, allowing treatment strategies for subsets of patients with CS receiving ECMO to be developed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
National Natural Science Foundation of China (No. 82170400 to Xiaotong Hou): The mechanism of erythroid precursors regulate negatively monocytes immune function through Galectin-9-TIM3 pathway. National Natural Science Foundation of China (No. 81870305 to Xiaotong Hou): The negative regulation mechanism of co-inhibitory molecule TIGIT on the function of inflammatory monocytes in patients supported with ECMO. Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support, Code: ZYLX202111. Beijing Hospitals Authority "Ascent Plan", Code: FDL20190601. Beijing Key Specialist Project for Major Epidemic Prevention and Control Supported by the National Key Research and Development Program of China (No. 2021YFC2701703) Beijing Nova Program (No. 2022064) Social Development Science and Technology Project (CYSF2215) from Chaoyang District Bureau of Science and Technology and Information Technology
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional ethics committee/review board of the Beijing Anzhen Hospital. Informed consent for demographic, physiological and hospital-outcome data analyses was not obtained because this observational study did not modify existing diagnostic or therapeutic strategies. However, patients and/or relatives were informed about the anonymous data collection and that they could decline inclusion.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data referred to in the manuscript is objective and true,and will be available to reviewers if necessary.
Abbreviations
- VA-ECMO
- Venoarterial extracorporeal membrane oxygenation
- CS
- cardiogenic shock
- PLT
- platelet count
- AST
- aspartic acid transaminase
- IL-6
- Interleukin-6
- PT
- prothrombin time
- ML
- Machine learning
- SAVE
- The survival after VA-ECMO score
- AMI
- acute myocardial infarction
- REMEMBER
- pRedicting mortality in patients undergoing veno-arterial Extracorporeal MEMBrane oxygenation after coronary artEry bypass gRafting
- ENCOURAGE
- prEdictioN of Cardiogenic shock OUtcome foR Acute myocardial infarction patients salvaGed by VA-ECMO score
- ARDS
- acute respiratory distress syndrome
- LVEF
- left ventricular ejection fraction
- LVEDD
- left ventricular end-diastolic diameter
- NYHA
- New York Heart Association Functional Classification
- VIS
- the vasoactive inotropic score
- ABG
- arterial blood gas
- MAP
- mean arterial pressure
- TSNE plot
- t-distributed stochastic neighbor embedding plot
- IQR
- Interquartile range
- CRRT
- Continuous renal replacement therapy
- SOFA
- The Sepsis-related Organ Failure Assessment score
- ROS
- reactive oxygen species
- ox-LDL
- oxidized low-density lipoprotein
- MDA
- malondialdehyde
- MODS
- multiple organ disorder syndrome
- IABP
- intra-aortic balloon pump
- CPB
- cardiopulmonary bypass
- CABG
- Coronary artery bypass grafting
- ICU
- Intensive care unit
